middle.news
Can Lumos Diagnostics Turn Losses Around with FebriDx’s US Breakthrough?
10:02am on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
Can Lumos Diagnostics Turn Losses Around with FebriDx’s US Breakthrough?
10:02am on Friday 27th of February, 2026 AEDT
Key Points
Half-year loss rises 74% to US$4.88 million
Revenues dip 3% to US$6.12 million with contract services down 19%
FebriDx sales double, supported by US$317 million Phase Scientific deal
FDA CLIA Waiver decision for FebriDx expected by March 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
LUMOS DIAGNOSTICS HOLDINGS (ASX:LDX)
OPEN ARTICLE